Pennsylvania is currently home to 3306 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: St. Luke's University Health Network, Bethlehem, Pennsylvania
Conditions: Breast Neoplasms
Register for Updates
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777
Recruiting
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/17/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Crohn's Disease
Register for Updates
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
NCT05238116
Recruiting
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Clinical Research Site 002, Philadelphia, Pennsylvania
Conditions: Refractory IPA
Register for Updates
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696
Recruiting
This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT05123482
Recruiting
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Research Site, Pittsburgh, Pennsylvania
Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma, Squamous Non-Small Cell Lung Cancer
Register for Updates
huCART19-IL18 in CD19+ Cancers
NCT04684563
Recruiting
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/17/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Chronic Migraine
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: Frontier Clinical Research, LLC, Scottdale, Pennsylvania
Conditions: Migraine
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: Frontier Clinical Research, LLC, Scottdale, Pennsylvania
Conditions: Migraine
Register for Updates
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
NCT04380740
Recruiting
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/17/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Graft Vs Host Disease
Register for Updates
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
NCT04302025
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: AHN Cancer Institute ? Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Non-small Cell Lung Cancer
Register for Updates
Investigating Dupilumab's Effect in Asthma by Genotype
NCT03694158
Recruiting
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Asthma
Register for Updates